cabozantinib,atezolizumab
roche
['renal,(-adrenal)', 'contact-03', 'atezo', 'cabozantinib']
 atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (contact-03): a multicentre, randomised, open-label, phase 3 trial #asco23 
Leader GU @InstitutoRoffo #GU #RCC #prostate #bladder #testis #GUcsm #clinicaltrials #Immunotherapy #PrecisionMedicine #OncoAlert #OncoReporte
Views Mine